CytomX Therapeutics Inc (NASDAQ:CTMX) Given Consensus Recommendation of “Buy” by Brokerages

CytomX Therapeutics Inc (NASDAQ:CTMX) has earned an average rating of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $20.91.

A number of analysts have recently issued reports on CTMX shares. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. BidaskClub cut shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. Cowen reiterated a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, August 7th. Mizuho reiterated a “buy” rating and issued a $16.00 price objective on shares of CytomX Therapeutics in a research note on Monday, August 12th. Finally, ValuEngine upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

A number of institutional investors have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. increased its holdings in CytomX Therapeutics by 3.3% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 73,151 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 2,350 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in CytomX Therapeutics by 19.6% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 19,024 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 3,120 shares during the period. Bank of Montreal Can bought a new position in CytomX Therapeutics in the 2nd quarter valued at about $42,000. UBS Asset Management Americas Inc. increased its holdings in CytomX Therapeutics by 16.2% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 28,564 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 3,974 shares during the period. Finally, Northern Trust Corp increased its holdings in CytomX Therapeutics by 0.7% in the 2nd quarter. Northern Trust Corp now owns 546,078 shares of the biotechnology company’s stock valued at $6,127,000 after buying an additional 4,058 shares during the period. Institutional investors and hedge funds own 78.50% of the company’s stock.

Shares of NASDAQ CTMX traded up $0.32 during mid-day trading on Monday, reaching $7.04. 457,900 shares of the company were exchanged, compared to its average volume of 429,820. The company’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $9.86. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $323.32 million, a P/E ratio of -3.47 and a beta of 0.68. CytomX Therapeutics has a twelve month low of $6.64 and a twelve month high of $19.75.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). The company had revenue of $9.01 million for the quarter, compared to analyst estimates of $15.11 million. CytomX Therapeutics had a negative return on equity of 77.05% and a negative net margin of 158.05%. As a group, equities research analysts expect that CytomX Therapeutics will post -2.01 EPS for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: Why is the price-sales ratio important?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.